Logo image of VLA.PA

VALNEVA SE (VLA.PA) Stock Fundamental Analysis

Europe - EPA:VLA - FR0004056851 - Common Stock

4.212 EUR
-0.13 (-3.08%)
Last: 10/20/2025, 7:00:00 PM
Fundamental Rating

2

Overall VLA gets a fundamental rating of 2 out of 10. We evaluated VLA against 76 industry peers in the Biotechnology industry. Both the profitability and financial health of VLA have multiple concerns. VLA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VLA has reported negative net income.
VLA had a negative operating cash flow in the past year.
In the past 5 years VLA always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: VLA reported negative operating cash flow in multiple years.
VLA.PA Yearly Net Income VS EBIT VS OCF VS FCFVLA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

With a Return On Assets value of -18.09%, VLA perfoms like the industry average, outperforming 55.26% of the companies in the same industry.
Looking at the Return On Equity, with a value of -45.87%, VLA is in line with its industry, outperforming 57.89% of the companies in the same industry.
Industry RankSector Rank
ROA -18.09%
ROE -45.87%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
VLA.PA Yearly ROA, ROE, ROICVLA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

VLA's Gross Margin of 48.94% is in line compared to the rest of the industry. VLA outperforms 52.63% of its industry peers.
VLA's Gross Margin has declined in the last couple of years.
VLA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
VLA.PA Yearly Profit, Operating, Gross MarginsVLA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VLA has more shares outstanding
The number of shares outstanding for VLA has been increased compared to 5 years ago.
The debt/assets ratio for VLA has been reduced compared to a year ago.
VLA.PA Yearly Shares OutstandingVLA.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
VLA.PA Yearly Total Debt VS Total AssetsVLA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

VLA has an Altman-Z score of -0.17. This is a bad value and indicates that VLA is not financially healthy and even has some risk of bankruptcy.
VLA has a Altman-Z score (-0.17) which is comparable to the rest of the industry.
VLA has a Debt/Equity ratio of 0.80. This is a neutral value indicating VLA is somewhat dependend on debt financing.
The Debt to Equity ratio of VLA (0.80) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF N/A
Altman-Z -0.17
ROIC/WACCN/A
WACC8.1%
VLA.PA Yearly LT Debt VS Equity VS FCFVLA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 2.27 indicates that VLA has no problem at all paying its short term obligations.
VLA has a Current ratio (2.27) which is in line with its industry peers.
VLA has a Quick Ratio of 1.77. This is a normal value and indicates that VLA is financially healthy and should not expect problems in meeting its short term obligations.
VLA has a Quick ratio of 1.77. This is comparable to the rest of the industry: VLA outperforms 47.37% of its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.77
VLA.PA Yearly Current Assets VS Current LiabilitesVLA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

VLA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -95.65%.
VLA shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.49%.
Measured over the past years, VLA shows a small growth in Revenue. The Revenue has been growing by 6.09% on average per year.
EPS 1Y (TTM)-95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
Revenue 1Y (TTM)31.49%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%26.98%

3.2 Future

The Earnings Per Share is expected to grow by 53.87% on average over the next years. This is a very strong growth
Based on estimates for the next years, VLA will show a quite strong growth in Revenue. The Revenue will grow by 17.97% on average per year.
EPS Next Y-580.55%
EPS Next 2Y-96.15%
EPS Next 3Y120.41%
EPS Next 5Y53.87%
Revenue Next Year4.16%
Revenue Next 2Y12.8%
Revenue Next 3Y28.76%
Revenue Next 5Y17.97%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VLA.PA Yearly Revenue VS EstimatesVLA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
VLA.PA Yearly EPS VS EstimatesVLA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VLA.PA Price Earnings VS Forward Price EarningsVLA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VLA.PA Per share dataVLA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

VLA's earnings are expected to grow with 120.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-96.15%
EPS Next 3Y120.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE

EPA:VLA (10/20/2025, 7:00:00 PM)

4.212

-0.13 (-3.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-13 2025-11-13
Inst Owners22.62%
Inst Owner ChangeN/A
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap361.66M
Analysts84
Price Target7 (66.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.78%
Min EPS beat(2)56.68%
Max EPS beat(2)62.87%
EPS beat(4)3
Avg EPS beat(4)14.13%
Min EPS beat(4)-115.24%
Max EPS beat(4)62.87%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)-23.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)21.69%
Min Revenue beat(2)16.4%
Max Revenue beat(2)26.97%
Revenue beat(4)3
Avg Revenue beat(4)10.09%
Min Revenue beat(4)-4.78%
Max Revenue beat(4)26.97%
Revenue beat(8)4
Avg Revenue beat(8)1.3%
Revenue beat(12)7
Avg Revenue beat(12)19.63%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.3%
PT rev (3m)-2.46%
EPS NQ rev (1m)10%
EPS NQ rev (3m)25%
EPS NY rev (1m)4.07%
EPS NY rev (3m)2.41%
Revenue NQ rev (1m)-0.71%
Revenue NQ rev (3m)-2.09%
Revenue NY rev (1m)0.81%
Revenue NY rev (3m)-2.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.24
P/FCF N/A
P/OCF N/A
P/B 1.94
P/tB 2.22
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS3.39
BVpS2.17
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.09%
ROE -45.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.94%
FCFM N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.71%
Cap/Sales 5.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.77
Altman-Z -0.17
F-Score4
WACC8.1%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
EPS Next Y-580.55%
EPS Next 2Y-96.15%
EPS Next 3Y120.41%
EPS Next 5Y53.87%
Revenue 1Y (TTM)31.49%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%26.98%
Revenue Next Year4.16%
Revenue Next 2Y12.8%
Revenue Next 3Y28.76%
Revenue Next 5Y17.97%
EBIT growth 1Y-49.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-280.12%
EBIT Next 3Y59.13%
EBIT Next 5Y30.38%
FCF growth 1Y88.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.27%
OCF growth 3YN/A
OCF growth 5YN/A